Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα.

Britschgi A, Duss S, Kim S, Couto JP, Brinkhaus H, Koren S, De Silva D, Mertz KD, Kaup D, Varga Z, Voshol H, Vissieres A, Leroy C, Roloff T, Stadler MB, Scheel CH, Miraglia LJ, Orth AP, Bonamy GM, Reddy VA, Bentires-Alj M.

Nature. 2017 Jan 26;541(7638):541-545. doi: 10.1038/nature20829. Epub 2017 Jan 9.

2.

Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.

Leroy C, Ramos P, Cornille K, Bonenfant D, Fritsch C, Voshol H, Bentires-Alj M.

Breast Cancer Res. 2016 Apr 5;18(1):41. doi: 10.1186/s13058-016-0697-1.

3.

CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency.

Bidinosti M, Botta P, Krüttner S, Proenca CC, Stoehr N, Bernhard M, Fruh I, Mueller M, Bonenfant D, Voshol H, Carbone W, Neal SJ, McTighe SM, Roma G, Dolmetsch RE, Porter JA, Caroni P, Bouwmeester T, Lüthi A, Galimberti I.

Science. 2016 Mar 11;351(6278):1199-203. doi: 10.1126/science.aad5487. Epub 2016 Feb 4.

4.

Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.

Herkert B, Kauffmann A, Mollé S, Schnell C, Ferrat T, Voshol H, Juengert J, Erasimus H, Marszalek G, Kazic-Legueux M, Billy E, Ruddy D, Stump M, Guthy D, Ristov M, Calkins K, Maira SM, Sellers WR, Hofmann F, Hall MN, Brachmann SM.

Cancer Res. 2016 Jan 15;76(2):390-402. doi: 10.1158/0008-5472.CAN-14-3358. Epub 2015 Nov 17.

5.

Proteomics in Pharmaceutical Research and Development.

Cutler P, Voshol H.

Proteomics Clin Appl. 2015 Aug;9(7-8):641-2. doi: 10.1002/prca.201570043. No abstract available.

PMID:
26178466
6.

ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer.

Bill A, Gutierrez A, Kulkarni S, Kemp C, Bonenfant D, Voshol H, Duvvuri U, Gaither LA.

Oncotarget. 2015 Apr 20;6(11):9173-88.

7.

Scalable production in human cells and biochemical characterization of full-length normal and mutant huntingtin.

Huang B, Lucas T, Kueppers C, Dong X, Krause M, Bepperling A, Buchner J, Voshol H, Weiss A, Gerrits B, Kochanek S.

PLoS One. 2015 Mar 23;10(3):e0121055. doi: 10.1371/journal.pone.0121055. eCollection 2015.

8.

Proteomics in pharmaceutical research and development.

Cutler P, Voshol H.

Proteomics Clin Appl. 2015 Aug;9(7-8):643-50. doi: 10.1002/prca.201400181. Epub 2015 May 26. Review.

PMID:
25763573
9.

CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases.

Leroy C, Shen Q, Strande V, Meyer R, McLaughlin ME, Lezan E, Bentires-Alj M, Voshol H, Bonenfant D, Alex Gaither L.

Oncogene. 2015 Oct 29;34(44):5593-8. doi: 10.1038/onc.2015.19. Epub 2015 Mar 2.

10.

Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases.

Sausgruber N, Coissieux MM, Britschgi A, Wyckoff J, Aceto N, Leroy C, Stadler MB, Voshol H, Bonenfant D, Bentires-Alj M.

Oncogene. 2015 Apr 23;34(17):2272-8. doi: 10.1038/onc.2014.170. Epub 2014 Jun 16.

PMID:
24931162
11.

Mammary tumor formation and metastasis evoked by a HER2 splice variant.

Alajati A, Sausgruber N, Aceto N, Duss S, Sarret S, Voshol H, Bonenfant D, Bentires-Alj M.

Cancer Res. 2013 Sep 1;73(17):5320-7. doi: 10.1158/0008-5472.CAN-12-3186. Epub 2013 Jul 18.

12.

The tyrosine phosphatase PTPN14 is a negative regulator of YAP activity.

Michaloglou C, Lehmann W, Martin T, Delaunay C, Hueber A, Barys L, Niu H, Billy E, Wartmann M, Ito M, Wilson CJ, Digan ME, Bauer A, Voshol H, Christofori G, Sellers WR, Hofmann F, Schmelzle T.

PLoS One. 2013 Apr 16;8(4):e61916. doi: 10.1371/journal.pone.0061916. Print 2013.

13.

Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Andraos R, Qian Z, Bonenfant D, Rubert J, Vangrevelinghe E, Scheufler C, Marque F, Régnier CH, De Pover A, Ryckelynck H, Bhagwat N, Koppikar P, Goel A, Wyder L, Tavares G, Baffert F, Pissot-Soldermann C, Manley PW, Gaul C, Voshol H, Levine RL, Sellers WR, Hofmann F, Radimerski T.

Cancer Discov. 2012 Jun;2(6):512-523. doi: 10.1158/2159-8290.CD-11-0324. Epub 2012 May 3.

14.

Inhibition of dengue virus polymerase by blocking of the RNA tunnel.

Niyomrattanakit P, Chen YL, Dong H, Yin Z, Qing M, Glickman JF, Lin K, Mueller D, Voshol H, Lim JY, Nilar S, Keller TH, Shi PY.

J Virol. 2010 Jun;84(11):5678-86. doi: 10.1128/JVI.02451-09. Epub 2010 Mar 17.

15.

N-sulfonylanthranilic acid derivatives as allosteric inhibitors of dengue viral RNA-dependent RNA polymerase.

Yin Z, Chen YL, Kondreddi RR, Chan WL, Wang G, Ng RH, Lim JY, Lee WY, Jeyaraj DA, Niyomrattanakit P, Wen D, Chao A, Glickman JF, Voshol H, Mueller D, Spanka C, Dressler S, Nilar S, Vasudevan SG, Shi PY, Keller TH.

J Med Chem. 2009 Dec 24;52(24):7934-7. doi: 10.1021/jm901044z.

PMID:
20014868
16.

Antibody-based proteomics: analysis of signaling networks using reverse protein arrays.

Voshol H, Ehrat M, Traenkle J, Bertrand E, van Oostrum J.

FEBS J. 2009 Dec;276(23):6871-9. doi: 10.1111/j.1742-4658.2009.07395.x. Epub 2009 Oct 26. Review.

17.

Tracing pathway activities with kinase inhibitors and reverse phase protein arrays.

van Oostrum J, Calonder C, Rechsteiner D, Ehrat M, Mestan J, Fabbro D, Voshol H.

Proteomics Clin Appl. 2009 Apr;3(4):412-22. doi: 10.1002/prca.200800070. Epub 2008 Dec 9.

PMID:
21136968
18.

Triggering the succinate receptor GPR91 on dendritic cells enhances immunity.

Rubic T, Lametschwandtner G, Jost S, Hinteregger S, Kund J, Carballido-Perrig N, Schwärzler C, Junt T, Voshol H, Meingassner JG, Mao X, Werner G, Rot A, Carballido JM.

Nat Immunol. 2008 Nov;9(11):1261-9. doi: 10.1038/ni.1657. Epub 2008 Sep 28.

PMID:
18820681
19.

Guidelines for reporting the use of gel electrophoresis in proteomics.

Gibson F, Anderson L, Babnigg G, Baker M, Berth M, Binz PA, Borthwick A, Cash P, Day BW, Friedman DB, Garland D, Gutstein HB, Hoogland C, Jones NA, Khan A, Klose J, Lamond AI, Lemkin PF, Lilley KS, Minden J, Morris NJ, Paton NW, Pisano MR, Prime JE, Rabilloud T, Stead DA, Taylor CF, Voshol H, Wipat A, Jones AR.

Nat Biotechnol. 2008 Aug;26(8):863-4. doi: 10.1038/nbt0808-863. No abstract available.

20.

LC-MALDI MS and MS/MS--an efficient tool in proteome analysis.

Mueller DR, Voshol H, Waldt A, Wiedmann B, Van Oostrum J.

Subcell Biochem. 2007;43:355-80. Review.

PMID:
17953403
21.

From proteomics to systems biology of bacterial pathogens: approaches, tools, and applications.

Plikat U, Voshol H, Dangendorf Y, Wiedmann B, Devay P, Müller D, Wirth U, Szustakowski J, Chirn GW, Inverardi B, Puyang X, Brown K, Kamp H, Hoving S, Ruchti A, Brendlen N, Peterson R, Buco J, Oostrum Jv, Peitsch MC.

Proteomics. 2007 Mar;7(6):992-1003.

PMID:
17370256
22.

Reduced susceptibility of Haemophilus influenzae to the peptide deformylase inhibitor LBM415 can result from target protein overexpression due to amplified chromosomal def gene copy number.

Dean CR, Narayan S, Richards J, Daigle DM, Esterow S, Leeds JA, Kamp H, Puyang X, Wiedmann B, Mueller D, Voshol H, van Oostrum J, Wall D, Koehn J, Dzink-Fox J, Ryder NS.

Antimicrob Agents Chemother. 2007 Mar;51(3):1004-10. Epub 2007 Jan 12.

23.

Identification of apolipoprotein A-I as a "STOP" signal for myopia.

Bertrand E, Fritsch C, Diether S, Lambrou G, Müller D, Schaeffel F, Schindler P, Schmid KL, van Oostrum J, Voshol H.

Mol Cell Proteomics. 2006 Nov;5(11):2158-66. Epub 2006 Aug 18.

24.

Evaluation of biomarker discovery approaches to detect protein biomarkers of acute renal allograft rejection.

Voshol H, Brendlen N, Müller D, Inverardi B, Augustin A, Pally C, Wieczorek G, Morris RE, Raulf F, van Oostrum J.

J Proteome Res. 2005 Jul-Aug;4(4):1192-9.

PMID:
16083269
25.

Neuroproteomics: expression profiling of the brain's proteomes in health and disease.

Kim SI, Voshol H, van Oostrum J, Hastings TG, Cascio M, Glucksman MJ.

Neurochem Res. 2004 Jun;29(6):1317-31. Review.

PMID:
15176488
26.

Proteomics-based target identification: bengamides as a new class of methionine aminopeptidase inhibitors.

Towbin H, Bair KW, DeCaprio JA, Eck MJ, Kim S, Kinder FR, Morollo A, Mueller DR, Schindler P, Song HK, van Oostrum J, Versace RW, Voshol H, Wood J, Zabludoff S, Phillips PE.

J Biol Chem. 2003 Dec 26;278(52):52964-71. Epub 2003 Oct 8.

27.

Proteomics in the discovery of new therapeutic targets for psychiatric disease.

Voshol H, Glucksman MJ, van Oostrum J.

Curr Mol Med. 2003 Aug;3(5):447-58. Review.

PMID:
12942998
28.

Identification of a peptide mimic of the L2/HNK-1 carbohydrate epitope.

Simon-Haldi M, Mantei N, Franke J, Voshol H, Schachner M.

J Neurochem. 2002 Dec;83(6):1380-8.

29.

Preparative two-dimensional gel electrophoresis at alkaline pH using narrow range immobilized pH gradients.

Hoving S, Gerrits B, Voshol H, Müller D, Roberts RC, van Oostrum J.

Proteomics. 2002 Feb;2(2):127-34.

PMID:
11840558
30.

The human genome: proteomics.

Van Oostrum J, Voshol H.

Am J Psychiatry. 2002 Feb;159(2):208. No abstract available.

PMID:
11823260
31.

Fluoroaluminate stimulates phosphorylation of p130 Cas and Fak and increases attachment and spreading of preosteoblastic MC3T3-E1 cells.

Freitas F, Jeschke M, Majstorovic I, Mueller DR, Schindler P, Voshol H, Van Oostrum J, Susa M.

Bone. 2002 Jan;30(1):99-108.

PMID:
11792571
32.

Phosphorylation disrupts the central helix in Op18/stathmin and suppresses binding to tubulin.

Steinmetz MO, Jahnke W, Towbin H, García-Echeverría C, Voshol H, Müller D, van Oostrum J.

EMBO Rep. 2001 Jun;2(6):505-10.

33.

Epitope diversity of N-glycans from bovine peripheral myelin glycoprotein P0 revealed by mass spectrometry and nano probe magic angle spinning 1H NMR spectroscopy.

Gallego RG, Blanco JL, Thijssen-van Zuylen CW, Gotfredsen CH, Voshol H, Duus JØ, Schachner M, Vliegenthart JF.

J Biol Chem. 2001 Aug 17;276(33):30834-44. Epub 2001 Jun 15.

34.

Isotope-tagged cross-linking reagents. A new tool in mass spectrometric protein interaction analysis.

Müller DR, Schindler P, Towbin H, Wirth U, Voshol H, Hoving S, Steinmetz MO.

Anal Chem. 2001 May 1;73(9):1927-34.

PMID:
11354472
35.

Towards high performance two-dimensional gel electrophoresis using ultrazoom gels.

Hoving S, Voshol H, van Oostrum J.

Electrophoresis. 2000 Jul;21(13):2617-21.

PMID:
10949138
36.

Mass spectrometric characterization of stathmin isoforms separated by 2D PAGE.

Müller DR, Schindler P, Coulot M, Voshol H, van Oostrum J.

J Mass Spectrom. 1999 Apr;34(4):336-45.

PMID:
10226362
37.
38.

Structure of the HNK-1 carbohydrate epitope on bovine peripheral myelin glycoprotein P0.

Voshol H, van Zuylen CW, Orberger G, Vliegenthart JF, Schachner M.

J Biol Chem. 1996 Sep 20;271(38):22957-60.

39.

The glycosylation profile of interleukin-2 activated human lymphocytes correlates to their anti-tumor activity.

Voshol H, Dullens HF, Den Otter W, Vliegenthart JF.

Anticancer Res. 1996 Jan-Feb;16(1):155-9.

PMID:
8615602
40.

Human natural killer cells: a convenient purification procedure and the influence of cryopreservation on cytotoxic activity.

Voshol H, Dullens HF, Den Otter W, Vliegenthart JF.

J Immunol Methods. 1993 Sep 27;165(1):21-30.

PMID:
8409465
41.

HB4 antibody recognizes a carbohydrate structure on lymphocyte surface proteins related to HB6, CDw75, and CD76 antigens.

De Lau WB, Kuipers J, Voshol H, Clevers H, Bast BJ.

J Immunol. 1993 Jun 1;150(11):4911-9.

PMID:
8496593
43.

Different isoforms of an apoprotein (apolipophorin III) associate with lipoproteins in Locusta migratoria.

Van der Horst DJ, Van Doorn JM, Voshol H, Kanost MR, Ziegler R, Beenakkers AM.

Eur J Biochem. 1991 Mar 14;196(2):509-17.

Supplemental Content

Loading ...
Support Center